Recent studies offer new insights into ALK detection methods and related treatments. Screening for the non-small cell lung cancer (NSCLC) subtype has been at the forefront of NSCLC research, and ...
Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation Patients age ≥ 18 years with two or more visits ...
Wiesbaden, Germany - Abbott (NYSE: ABT) today announced the availability of a new molecular test in the European Union and New Zealand designed to identify the presence of gene rearrangements ...
A novel technique for detecting ALK rearrangements in non-small cell lung cancers (NSCLCs) has been developed that is more sensitive and easier to perform than currently available techniques. The ...
ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis ® ALK Break Apart FISH Probe Kit, allowing the ...
Simultaneous Approval of New Treatment and Companion Diagnostic Represents Significant Advance in Personalized Medicine for Patients with Non-Small-Cell Lung Cancer ABBOTT PARK, Ill., Aug. 26, 2011 ...
Routine testing with both fluorescent in situ hybridization and immunohistochemistry may enhance the detection of ALK-positive non-small cell lung cancer, new research suggests. Accurate determination ...
LOS ANGELES--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, today announced that it has expanded its ...
Circulating Human Papillomavirus DNA as a Biomarker of Response in Patients With Locally Advanced Cervical Cancer Treated With Definitive Chemoradiation Patients age ≥ 18 years with two or more visits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback